Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold

 
• By Alaric DeArment
  
Foghorn announced a partial clinical hold on its Phase I AML/MDS study following a patient death • Source: Shutterstock

More from Clinical Trials

More from R&D